For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Investing.com -- A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) resigned Monday, expressing concerns about how COVID-19 and RSV hospitalization data would be used by ...

Fiona Havers, who oversees CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

A Seattle infectious disease doctor, whose work was pivotal early in the COVID pandemic, shares more on her experience with ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated ...

Tourists in Israel and Lebanon have found themselves stranded at airports amid Israel's conflict with Iran. Fiona Jones ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Dr. Lbiati's appointment signals a new chapter for Hepion-one focused on strategic renewal, value creation, and diagnostic ...

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

Visit ESPN for RSV Eintracht live scores, video highlights, and latest news. Find standings and the full 2024-25 season schedule.